Biodegradable polymer based novel drug delivery systems brought a considerable attention in enhancing the therapeutic efficacy and bioavailability of various drugs. 14-deoxy 11, 12-didehydro andrographolide(poorly wat...Biodegradable polymer based novel drug delivery systems brought a considerable attention in enhancing the therapeutic efficacy and bioavailability of various drugs. 14-deoxy 11, 12-didehydro andrographolide(poorly water soluble compound) loaded polycaprolactone(nanoDDA) was synthesized using the solvent evaporation technique. Nano-DDA was characterized by scanning electron microscopy(SEM) and dynamic light scattering(DLS) studies. Fourier Transform InfraRed Spectroscopy(FTIR) was used to investigate the structural interaction between the drug and the polymer. Functional characterization of the formulation was determined using drug content, cellular uptake and in vitro drug release. 2-deoxy-D-[1-~3H] glucose uptake assay was carried out to assess the antidiabetic potential of nano-DDA in L6 myotubes.The nano-DDA displayed spherical shape with a smooth surface(252.898 nm diameter), zeta potential, encapsulation and loading efficiencies of -38.9 mV, 91.98 ± 0.13% and 15.09 ± 0.18% respectively. No structural alteration between the drug and the polymer was evidenced(FTIR analysis). Confocal microscopy studies with rhodamine 123 loaded polycaprolactone nanoparticles(Rh123-PCL NPs) revealed the internalization of Rh123-PCL NPs in a time dependent manner in L6 myoblasts. A dose dependent increase in glucose uptake was observed for nano-DDA with a maximal uptake of 108.54 ± 1.42% at 100 nM on L6 myotubes, thereby proving its anti-diabetic efficacy. A biphasic pattern of in vitro drug release demonstrated an initial burst release at 24 h followed by a sustained release for up to 11 days. To conclude,our results revealed that nano-DDA formulation can be a potent candidate for antidiabetic drug delivery.展开更多
目的探讨新生儿呼吸窘迫综合征(NRDS)患儿肺超声纹理特征、肺部12分区超声评分与预后不良的相关性,并分析其对预后不良风险的预测价值。方法选取2021年8月至2024年12月南阳市第一人民医院128例NRDS患儿为研究对象,根据预后情况分为预后...目的探讨新生儿呼吸窘迫综合征(NRDS)患儿肺超声纹理特征、肺部12分区超声评分与预后不良的相关性,并分析其对预后不良风险的预测价值。方法选取2021年8月至2024年12月南阳市第一人民医院128例NRDS患儿为研究对象,根据预后情况分为预后良好组、预后不良组。比较两组临床资料、肺超声纹理特征、肺部12分区超声评分。采用列联相关性/Spearman相关性分析肺超声纹理特征、肺部12分区超声评分与NRDS患儿病情程度的关系。logistic回归分析预后不良风险的影响因素。采用受试者工作特征(ROC)曲线及曲线下面积(AUC)评价肺超声纹理特征、肺部12分区超声评分对预后不良风险的预测价值。结果128例NRDS患儿治疗后预后良好98例,预后不良30例;预后不良组胎龄、出生体重、出生1 min Apgar评分、动脉血氧分压(PaO_(2))、氧合指数低于预后良好组,动脉血二氧化碳分压(PaCO_(2))、持续气道正压通气(CPAP)时间、有创机械通气占比高于预后良好组(P<0.05);预后不良组对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分高于预后良好组(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分与出生1 min Apgar评分、PaO_(2)、氧合指数呈负相关,与PaCO_(2)呈正相关(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分是NRDS患儿预后不良风险的独立影响因素(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分联合预测预后不良风险的AUC高于各指标单项预测(P<0.001)。结论NRDS预后不良患儿肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差及肺部12分区超声评分较预后良好患儿升高,其与病情指标密切相关,且为预后不良风险的独立影响因素,联合检测其水平在预测患儿预后不良风险方面具有临床应用价值。展开更多
文摘Biodegradable polymer based novel drug delivery systems brought a considerable attention in enhancing the therapeutic efficacy and bioavailability of various drugs. 14-deoxy 11, 12-didehydro andrographolide(poorly water soluble compound) loaded polycaprolactone(nanoDDA) was synthesized using the solvent evaporation technique. Nano-DDA was characterized by scanning electron microscopy(SEM) and dynamic light scattering(DLS) studies. Fourier Transform InfraRed Spectroscopy(FTIR) was used to investigate the structural interaction between the drug and the polymer. Functional characterization of the formulation was determined using drug content, cellular uptake and in vitro drug release. 2-deoxy-D-[1-~3H] glucose uptake assay was carried out to assess the antidiabetic potential of nano-DDA in L6 myotubes.The nano-DDA displayed spherical shape with a smooth surface(252.898 nm diameter), zeta potential, encapsulation and loading efficiencies of -38.9 mV, 91.98 ± 0.13% and 15.09 ± 0.18% respectively. No structural alteration between the drug and the polymer was evidenced(FTIR analysis). Confocal microscopy studies with rhodamine 123 loaded polycaprolactone nanoparticles(Rh123-PCL NPs) revealed the internalization of Rh123-PCL NPs in a time dependent manner in L6 myoblasts. A dose dependent increase in glucose uptake was observed for nano-DDA with a maximal uptake of 108.54 ± 1.42% at 100 nM on L6 myotubes, thereby proving its anti-diabetic efficacy. A biphasic pattern of in vitro drug release demonstrated an initial burst release at 24 h followed by a sustained release for up to 11 days. To conclude,our results revealed that nano-DDA formulation can be a potent candidate for antidiabetic drug delivery.
文摘目的探讨新生儿呼吸窘迫综合征(NRDS)患儿肺超声纹理特征、肺部12分区超声评分与预后不良的相关性,并分析其对预后不良风险的预测价值。方法选取2021年8月至2024年12月南阳市第一人民医院128例NRDS患儿为研究对象,根据预后情况分为预后良好组、预后不良组。比较两组临床资料、肺超声纹理特征、肺部12分区超声评分。采用列联相关性/Spearman相关性分析肺超声纹理特征、肺部12分区超声评分与NRDS患儿病情程度的关系。logistic回归分析预后不良风险的影响因素。采用受试者工作特征(ROC)曲线及曲线下面积(AUC)评价肺超声纹理特征、肺部12分区超声评分对预后不良风险的预测价值。结果128例NRDS患儿治疗后预后良好98例,预后不良30例;预后不良组胎龄、出生体重、出生1 min Apgar评分、动脉血氧分压(PaO_(2))、氧合指数低于预后良好组,动脉血二氧化碳分压(PaCO_(2))、持续气道正压通气(CPAP)时间、有创机械通气占比高于预后良好组(P<0.05);预后不良组对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分高于预后良好组(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分与出生1 min Apgar评分、PaO_(2)、氧合指数呈负相关,与PaCO_(2)呈正相关(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分是NRDS患儿预后不良风险的独立影响因素(P<0.05);肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差、肺部12分区超声评分联合预测预后不良风险的AUC高于各指标单项预测(P<0.001)。结论NRDS预后不良患儿肺超声纹理特征对比度、集群阴影、差异性、逆差距、和方差及肺部12分区超声评分较预后良好患儿升高,其与病情指标密切相关,且为预后不良风险的独立影响因素,联合检测其水平在预测患儿预后不良风险方面具有临床应用价值。
